title: mTOR inhibition in T-cell lymphoma: a path(way) forward.
abstract: In this issue of Blood, Witzig et al report on the promising in vitro and in vivo activity of everolimus in T-cell lymphoma (TCL) and pave the way for future combination studies.
authors.affiliation: MEMORIAL SLOAN KETTERING CANCER CENTER.
authors.forename: Alison J
authors.initials: AJ
authors.lastname: Moskowitz
authors.affiliation: MEMORIAL SLOAN KETTERING CANCER CENTER.
authors.forename: Steven M
authors.identifier: http://orcid.org/0000-0002-6399-2006
authors.initials: SM
authors.lastname: Horwitz
mesh_terms: D000818:Animals; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D008297:Male; D046912:Multiprotein Complexes / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D020123:Sirolimus / Q000031:analogs & derivatives*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism*
chemical_list: D007166:Immunosuppressive Agents; D046912:Multiprotein Complexes; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus